In a report released yesterday, Gianluca Tucci from Haywood reiterated a Buy rating on WELL Health Technologies Corp, with a price target of C$8.50.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gianluca Tucci has given his Buy rating due to a combination of factors that strengthen WELL Health Technologies Corp’s growth outlook and risk profile. He views the materially enlarged $400M credit facility, supported by leading banks and extended to 2030, as a strong endorsement of the company’s strategy and balance sheet discipline. The added lending capacity provides substantial capital to pursue a sizeable pipeline of identified acquisitions, while management’s commitment to keeping leverage below 3.0x suggests growth can be funded without compromising financial stability.
Tucci also highlights the strategic acquisition of E-Consult Canada as a key driver of his positive view. By entering the Alberta e-consult market and increasing exposure to higher-margin, technology-driven services, WELL is accelerating its transition from a traditional clinic operator to a scalable digital health platform. This shift in revenue mix, combined with ample capital to execute on further consolidation opportunities, underpins his confidence in WELL’s ability to deliver on its 2026 growth thesis and supports his Buy recommendation.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a C$6.50 price target.